1ST Biotherapeutics

5 articles about 1ST Biotherapeutics

• 1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors

  12/14/2023

  1ST Biotherapeutics, Inc. announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.

• 1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)

  9/19/2023

  1ST Biotherapeutics, Inc. announced a Clinical Trial Collaboration and Supply Agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.

• 1ST Biotherapeutics and twoXAR Advance Three Novel Glioblastoma Treatment Candidates into In Vivo Testing in Less Than One Year

  2/25/2020

  Partnership Combines Shared Drug Discovery Expertise with Integrated Artificial Intelligence to Identify Promising Targets in Half the Time of Traditional R&D Approaches

• 1ST Biotherapeutics and twoXAR Form Co-Development Collaboration to Discover and Develop Treatments for Glioblastoma

  1/3/2019

  1ST Biotherapeutics, Inc. and twoXAR, Inc. today announced an agreement to jointly discover and develop novel, efficacious treatments to address unmet medical needs in glioblastoma multiforme (“glioblastoma”).

• 1ST Bio and Neuraly Collaborate to Advance Novel c-Abl Inhibitors for Parkinson's Disease

  10/25/2017

  1ST Bio today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson's disease.